13-dihydro-3′ aziridino anthracyclines

Details 13-dihydro-3′ aziridino anthracyclines 13-dihydro-3′ aziridino anthracyclines

1999-12-13

2001-07-10

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S006400

Reexamination Certificate

active

06258786

ABSTRACT:

The invention relates to anthracycline glycosides, to a process for their preparation and to pharmaceutical compositions containing them.
The invention provides anthracycline glycosides having the formula I:
wherein the wavy line means that the hydroxy group at 13-position may be at &agr; or &bgr; position, or a mixture thereof. Compounds of formula I comprise derivatives in which the hydroxy group at 13 position has configuration 13(S), 13(R), or a mixture of both 13(R) and 13(S) diastereoisomers, that is:
4-demethoxy-13(S/R)-dihydro-3′-deamino-3′-aziridinyl-4′
methansulfonyl daunorubicin (Ia),
4-demethoxy-13(S)-dihydro-3′-deamino-3′-aziridinyl-4′-methansulfonyl
daunorubicin (Ib) and
4-demethoxy-13(R)-dihydro-3′-deamino-3′-aziridinyl-4′-methansulfonyl
daunorubicin (Ic).
More preferably, the present invention provides anthracycline glycosides having the formula I as above defined characterized in that the 13-carbon atom is S, i.e. 4-demethoxy-13(S)-dihydro-3′-deamino-3′-aziridinyl-4′-methansulfonyl
daunorubicin (Ib).
The compounds of the formula I may be prepared by reducing the anthracycline of the formula II
in presence of a reductive agent, such as sodium borohydride, in a mixture of organic solvents, such as methylene chloride and methanol, preferably at a temperature below 50° C., more preferably at −70° C., and, if desired and necessary, by separating the resultant mixture of 13(R) and 13(S) compounds into the single diastereoisomer. For example, the single 13-dihydro diastereoisomers may be obtained by separating the mixture with high pressure liquid chromatography (HPLC). In particular, the HPLC separation may be carried out onto a reverse phase column , using a mixture of phosphate buffer, such as 10 mM K
2
HPO
4
adjusted to pH 7.0 with 85% H
3
PO
4
, and an organic solvent as mobile phase, such as tetrahydrofuran or acetonitrile.
The starting material for the preparation of the new anthracycline glycosides is 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methansulfonyl daunorubicin (II), and it is described in U.S. Pat. No. 5,532,218.
The invention further provides a pharmaceutical composition comprising an anthracycline glycoside of formula I in admixture with a pharmaceutically acceptable diluent or carrier. Conventional carriers and diluents may be used. The composition may be formulated and administered in conventional manner.
The compounds according to the invention are useful in methods of treatment of the human or animal body by therapy. They are useful as anti-tumor agents. They are useful in the treatment of leukemia and solid tumors, such as colon, colon-rectal, ovarian, mammary, prostate, lung, kidney and also melanoma tumors. A human can therefore be treated by a method comprising administering thereto a therapeutically effective amount of a compound of the invention. The condition of the human patient can thus be improved. The dosage to be given can be ascertained using known dosage ranges in the field of anthracyclines, modified by reference to the activity shown by the present compounds in in vitro and in vivo anti-tumor tests. Suitable dosages are generally in the range of 1 to 200 mg/m
2
body surface, preferably from 1 to 100 mg/m
2
, depending on the nature and severity of the disease being treated and on the general condition of the patient. The compounds of formula I were tested and found active in vitro against a panel of murine and human tumor cell lines, and in vivo on disseminated P388/DX murine leukemia.
In vitro and in vivo Activity of Ia
On a panel of murine and human tumor cell lines, Ia presents high cytotoxicity as shown by IC
50
values of Tab. 1. The results of in vivo test of Ia on disseminated P388/DX murine leukemia are shown in Tab.2.
TABLE 1
In vitro cytotoxicity of Ia
Ia
Cell Line
1
IC
2
50
ng/mL Mean ± SE
L1210
3
 3.76 ± 0.13
JURKAT
3
4.87 ± 0.7
CEM
3
5.86 ± 0.4
LoVo
4
20.3 ± 2 
1
Cells incubated with the compound for 1 h.
2
50% inhibitory concentration represents the mean ± SE from dose-response curves of at least two experiments
3
Growth inhibition determined by counting surviving cells.
4
Growth inhibition determined by SRB colorimetric assay.
TABLE 1
In vitro cytotoxicity of Ia
Ia
Cell Line
1
IC
2
50
ng/mL Mean ± SE
L1210
3
 3.76 ± 0.13
JURKAT
3
4.87 ± 0.7
CEM
3
5.86 ± 0.4
LoVo
4
20.3 ± 2 
1
Cells incubated with the compound for 1 h.
2
50% inhibitory concentration represents the mean ± SE from dose-response curves of at least two experiments
3
Growth inhibition determined by counting surviving cells.
4
Growth inhibition determined by SRB colorimetric assay.
The following example illustrates the invention.


REFERENCES:
patent: 4604381 (1986-08-01), Penco et al.
patent: 5532218 (1996-07-01), Bargiotti et al.
patent: 0 128 670 A1 (1984-12-01), None

Affiliated with

Also associated with

Rating

13-dihydro-3′ aziridino anthracyclines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 13-dihydro-3′ aziridino anthracyclines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 13-dihydro-3′ aziridino anthracyclines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2553096